Timing of the CKD Complications: A Longitudinal Analysis

Area of Science:

• Nephrology
• Endocrinology
• Metabolic Disorders

Background:

• Chronic kidney disease (CKD) is associated with numerous endocrine and metabolic complications.
• These complications significantly impact patient homeostasis and quality of life.
• Understanding the relationship between CKD stage and complication onset is crucial for timely intervention.

Purpose of the Study:

• To determine the influence of CKD stage on the emergence of specific complications.
• To identify estimated glomerular filtration rate (eGFR) thresholds for predicting complication onset.
• To establish evidence-based recommendations for complication screening in CKD patients.

Main Methods:

• An observational study involving 71 patients with 486 measurements.
• Data collected included anemia, BUN, hyperparathyroidism, hyperphosphatemia, hyperkalemia, and metabolic acidosis.
• Statistical analyses included Mann-Whitney, Pearson's Chi-Square, Spearman's correlation, GEE, Linear Mixed Models, and ROC curve analysis with Youden J index.

Main Results:

• CKD stage was significantly associated with all studied outcomes.
• Identified eGFR thresholds for complication prediction: anemia (37 ml/min/m2), hyperkalemia (34 ml/min/m2), hyperphosphatemia (26 ml/min/m2), and hyperparathyroidism (46 ml/min/m2).
• Baseline prevalence: hyperparathyroidism (69.1%), hyperkalemia (28.6%), hyperphosphatemia (15.5%).

Conclusions:

• Endocrine and metabolic complication screening in CKD should commence at the beginning of CKD stage III.
• Specific screening recommendations include hyperphosphatemia screening starting at CKD stage IV.
• These findings support proactive management strategies to mitigate CKD-related complications.